Biotech Daily

Tuesday August 11, 2026

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH UP: ORTHOCELL UP 10%; SYNTARA DOWN 11%**

*** STARPHARMA RIGHTS RAISE $32m**

*** LTR: 'SPONTAN 93% ERECTILE DYSFUNCTION RESPONSE - 64% POST-PROSTATECTOMY'**

*** ENLITIC $213k ENSIGHT US RADIOLOGY CONTRACT**

*** BELLASENO 1st 3-D SCAFFOLD 'PRIMARY BREAST AUGMENTATION'**

*** TRUSCREEN APPOINTS 2 AFRICA DISTRIBUTORS**

*** NEURIZON DRAWS $8m OF $17.5m DARE RDTI LOAN**

*** ARGENT TAKES $250k OF $11m CONVERTIBLE NOTE**

MARKET REPORT

The Australian stock market was up 0.19 percent on Tuesday August 11, 2026, with the ASX200 up 18.0 points to 9,250.6 points.

Twenty-two of the Biotech Daily Top 40 companies were up, 11 fell, six traded unchanged and one was untraded. All four Big Caps were up.

Orthocell was best, up 7.0 cents or 9.6 percent to 80 cents, with 682,290 shares traded.

Artrya climbed 8.8 percent; Amplia was up 7.1 percent; Atomo, Nova Eye, Optiscan and Racura rose five percent or more; Avita and Immutep improved more than four percent; Dimerix, Imricor, Pro Medicus and Resmed were up more than three percent; Cochlear, CSL, Mesoblast, Neuren and Paradigm rose more than two percent; Emvision, Nanosonics, Prescient, Resonance and Telix were up more than one percent; with Clarity, Clinuvel and Polynovo up by less than one percent.

Syntara led the falls, down 0.3 cents or 11.1 percent to 2.4 cents, with 10.9 million shares traded. 4D Medical and Starpharma lost more than seven percent; Cyclopharm and EBR shed more than six percent; Curvebeam fell 5.3 percent; Micro-X and Saluda were down more than three percent; Imugene and Medical Developments lost one percent or more; with Aroa down by 0.8 percent.

STARPHARMA

Starpharma says it has raised $32 million at 57 cents a share in its fully-underwritten, one-for-7.5, renounceable entitlement offer.

Last month, Starpharma says it expected to raise $32 million at 57 cents a share in a rights offer, a 25 percent discount to the last closing price (BD: Jul 15, 2026).

Today, the company said the funds would support its dendrimer enhanced product (DEP) oncology assets.

Starpharma said the underwriter Canaccord Genuity Australia would subscribe for $500,000 in shortfall shares in accordance with the underwriting agreement.

The company said the offer received "strong support from existing shareholders with a take-up rate of approximately 99 percent, including $5.4 million of applications under the over-subscription facility" and investors who applied for shares under the over-subscription facility could expect to receive the full amount of their applications.

Starpharma fell six cents or 7.55 percent to 73.5 cents with 10.7 million shares traded.

LTR PHARMA

LTR says 100 of 147 men (68.0%) in a retrospective, clinical study reported improved erectile hardness and or achieving penetration with its Spontan nasal spray.

In 2024, LTR said the first erectile dysfunction patients had been dosed with its Spontan nasal spray for erectile dysfunction under an Australian Therapeutic Goods Administration's special access scheme (BD: Aug 5, 2024).

Today, the company said the findings showed that its Spontan nasal spray formulation of vardenafil, marketed by Bayer as Levitra, "may provide an alternative treatment option for men who report inadequate results with conventional oral [erectile dysfunction] therapies such as sildenafil (Viagra) and tadalafil (Cialis)".

LTR said the cohort was "the largest real-world dataset reported for Spontan to-date".

The company said 42 of 45 men, or 93.3 percent, "seeking greater convenience and spontaneity" reported improved erectile hardness, with 56 of 87 post-prostatectomy patients, 64.4 percent, reporting an improved response.

LTR said 58 of 102 men, or 56.9 percent, achieved a response among the more difficult-to-treat subgroup who had previously reported inadequate efficacy with oral PDE5 inhibitor therapy.

The company said more than half of the difficult-to-treat men reported improved erectile hardness and/or achieving penetration with Spontan despite having previously reported inadequate results with conventional oral erectile dysfunction therapies.

LTR said while the results in post-prostatectomy patients were "not directly comparable with historical studies of oral PDE5 inhibitors, the findings highlight the potential role of rapid, non-invasive intranasal treatment with Spontan and Roxus for men experiencing [erectile dysfunction] following prostate cancer surgery".

The company said post-prostatectomy patients were "an important potential area for further clinical investigation and commercial development" and it would present the data at the Asia-Pacific Prostate Cancer Conference in Melbourne, August 13 to 15, 2026.

LTR said it continued "Australian real-world evidence collection, and implementation activities with Shed and Strive ahead of Roxus US commercial availability".

LTR executive chair Lee Rodne said the company regarded "this as an important real-world dataset for LTR".

"These findings provide an important clinical narrative as we engage urologists, men's health prescribers and commercial partners ahead of Roxus US availability," he said.

LTR was up 4.5 cents or 9.6 percent to 51.5 cents.

ENLITIC

Enlitic says it has an about $US50,000 ($A71,000) a year, three-year contract for the use of its Ensight software at Denver, Colorado's Radiology Imaging Associates.

Enlitic said that its internet cloud-based software was in use by Radiology Imaging, its second Ensight deployment since May, with further 'go-lives' expected by 2027.

The company said Radiology Imaging Associates was a physician-owned radiology group providing diagnostic and board-certified interventional radiology services in a network of imaging sites and clinical locations.

Enlitic said the initial annual recurring revenue of $US50,000 related to the first phase of the three-year agreement and was based on Radiology Imaging Associates' deployment of selected Ensight modules from the broader Ensight technology stack.

The company said the initial revenue "did not represent a full deployment of the Ensight platform across [Radiology Imaging] network of sites, users and workflows, which would be subject to any future expansion agreed between the parties".

Enlitic managing-director Michael Sistenich said the first US deployment of Ensight was "a significant milestone for Enlitic, and we are particularly pleased that Ensight is now live and in use by Radiology Imaging Associates".

"We see further upside in [annual recurring revenue], primarily through securing new customer agreements through Intelerad, but also in our own right," Mr Sistenich said.

Enlitic fell 0.1 cents or 20 percent to 0.4 cents with 1.6 million shares traded.

BELLASENO GmbH

Bellaseno says its 3-dimensional-printed scaffold has been used "in a world-first primary breast augmentation procedure" at Sydney's Macquarie University in a trial.

Last month, the Brisbane and Leipzig, Germany-based Bellaseno said it had treated 11 of more than 100 patients in its Australian trial of 3-dimensional-printed scaffolds for restorative breast surgery, with dozens more enrolled (BD: Jul 1, 2026).

At the time, a spokesperson for the company told Biotech Daily that Bellaseno's scaffolds were made from poly-capro-lactone with autologous fat grafting from the patient to restore breast volume and natural shape following the removal of implants, based on 2011 research from the Queensland University of Technology.

Today, Bellaseno said the Macquarie University patient was "the first participant treated in the planned 53-person primary augmentation component of the trial".

The company said the milestone extended the clinical investigation of its breast scaffold "beyond women undergoing revision surgery after the removal of traditional breast implants and into women seeking breast augmentation for the first time".

Bellaseno said the primary augmentation part of the trial would continue to recruit eligible participants and follow outcomes over time.

Bellaseno co-founding chief executive officer Dr Mohit Chhaya said the procedure was "a defining milestone in a journey that began with his Doctor of Philosophy research in Queensland in 2011 and has since been advanced by engineers, scientists, surgeons and patients across Australia and Europe".

"This is the point at which 15 years of research, engineering and clinical collaboration enters an important new chapter," Dr Chhaya said. "Our breast scaffold was developed to provide temporary structure and work in conjunction with a patient's own tissue."

"Through this trial, we are now evaluating whether that approach may broaden the future choices available to women who want breast volume restoration or augmentation but may not want a permanent implant," Dr Chhaya said.

Bellaseno is a private company.

TRUSCREEN GROUP

Truscreen says it has appointed two distributors for its cervical cancer screening technology, covering Nigeria, Ghana, Cote d'Ivoire and Rwanda.
Truscreen said the Lagos, Nigeria-based Zerocancer Professional Consult would distribute its portable, optical and electrical stimuli cervical cancer screening device in Nigeria, Ghana and Cote d'Ivoire, with the Kigali, Rwanda-based Biotech Medical Supply to distribute the device in Rwanda.
The company said the appointments expanded its distribution in Africa as it expected grant outcomes for projects in eight African nations, including Zimbabwe, South Africa, Eswatini, Rwanda, Nigeria, Ghana, Cote d'Ivoire and Kenya.
Truscreen said Nigeria regulatory approval was expected to take three to six months, with preparations underway for a 300-patient clinical evaluation to support applications for a national screening guideline and government screening programs.
The company said distribution appointments accelerated its expansion in Africa to potentially provide screening services in these jurisdictions by 2027.
Truscreen chief executive officer Martin Dillon said "the screening requirements and market opportunities in Africa is huge".
"Truscreen technology is well suited and positioned to support cervical cancer prevention initiatives in countries where laboratory infrastructure, pathology services and capacity remain insufficient, cervical cancer incidence and mortality is highest," Mr Dillon said.
Truscreen fell 0.1 cents or 7.7 percent to 1.2 cents with 1.7 million shares traded.

NEURIZON THERAPEUTICS

Neurizon says it has drawn-down an initial about $8.3 million of its up-to $17.5 million Dare Capital loan, secured against its Research and Development Tax Incentive.
Last week, Neurizon said it had a $17.5 million loan from Dare Capital Loan Fund secured against its expected Federal Research and Development Tax Incentive at 1.25 percent monthly interest and repayable by December 31, 2026 (BD: Aug 3, 2026).
Today, the company said the initial draw-down would support activities related to its phase II/III 'Healey' platform trial of NUZ-001 for amyotrophic lateral sclerosis (ALS).
Neurizon was up 0.05 cents or 0.7 percent to 6.85 cents.

ARGENT BIOPHARMA (FORMERLY MGC PHARMACEUTICALS)

Argent says it has drawn-down $250,000 from its $11 million convertible securities agreement with C/M Capital Master Fund and WVP Emerging Manager Onshore Fund.
Last year, Argent said it had an up-to $11 million finance agreement with the Cayman Islands-based C/M Capital and New York's WVP Emerging Manager Onshore Fund to fund its acquisition of Auscann and had drawn $3 million with the remaining funds available within 18 months; convertible at the lower of 10 cents or 90 percent of the lowest 15-day volume weighted average price to the conversion notice, but no less than four cents (BD: Nov 17, 2025).
Today, Argent said the $250,000 drawn-down was subject to shareholder approval.
The company said it would issue C/M Capital and WVP 2,010,724 unlisted options, each, exercisable at 9.325 cents each within 36 months from the date of issue.
Argent fell 0.3 cents or 7.3 percent to 3.8 cents.